There's a key price level to watch.
I found two very interesting takeaways from Monday's sharp market reversal.
Could Elon's move signal an eventual full blown takeover bid?
A chaotic news cycle has led to an equally wild swing in the share price of both names in the past week.
Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022
The department store retailer seems undervalued based on activist investor interest and the inclusion of Sephora shops in many of its locations.
The shares of the payments technology company wavered a bit on news of its interest in Pinterest but its technical signs still are good.
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
A possible business combination between the two entities doesn't appear to be exciting other investors, either.
Cybin Inc. and Draganfly Inc. soon will move up from the OTC markets to a major exchange; here are their prospects going forward.